- Home
- CNEY vs OGEN Comparison
CNEY vs OGEN Comparison
Compare CNEY & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNEY
- OGEN
- Stock Information
- Founded
- CNEY 2018
- OGEN 1996
- Country
- CNEY China
- OGEN United States
- Employees
- CNEY N/A
- OGEN N/A
- Industry
- CNEY Major Chemicals
- OGEN Biotechnology: Pharmaceutical Preparations
- Sector
- CNEY Industrials
- OGEN Health Care
- Exchange
- CNEY Nasdaq
- OGEN Nasdaq
- Market Cap
- CNEY 2.1M
- OGEN 2.5M
- IPO Year
- CNEY 2021
- OGEN N/A
- Fundamental
- Price
- CNEY $2.74
- OGEN $1.50
- Analyst Decision
- CNEY
- OGEN
- Analyst Count
- CNEY 0
- OGEN 0
- Target Price
- CNEY N/A
- OGEN N/A
- AVG Volume (30 Days)
- CNEY 49.8K
- OGEN 1.1M
- Earning Date
- CNEY 01-01-0001
- OGEN 08-08-2025
- Dividend Yield
- CNEY N/A
- OGEN N/A
- EPS Growth
- CNEY N/A
- OGEN N/A
- EPS
- CNEY N/A
- OGEN N/A
- Revenue
- CNEY $50,957,974.00
- OGEN N/A
- Revenue This Year
- CNEY N/A
- OGEN N/A
- Revenue Next Year
- CNEY N/A
- OGEN N/A
- P/E Ratio
- CNEY N/A
- OGEN N/A
- Revenue Growth
- CNEY N/A
- OGEN N/A
- 52 Week Low
- CNEY $2.53
- OGEN $1.35
- 52 Week High
- CNEY $40.00
- OGEN $75.60
- Technical
- Relative Strength Index (RSI)
- CNEY 42.93
- OGEN 27.35
- Support Level
- CNEY $2.59
- OGEN $1.35
- Resistance Level
- CNEY $2.84
- OGEN $4.19
- Average True Range (ATR)
- CNEY 0.17
- OGEN 0.43
- MACD
- CNEY 0.03
- OGEN -0.22
- Stochastic Oscillator
- CNEY 33.40
- OGEN 5.14
About CNEY CN Energy Group Inc.
CN Energy Group Inc along with its subsidiaries is a manufacturer and supplier of wood-based activated carbon that is used in pharmaceutical manufacturing, industrial manufacturing, water purification, environmental protection, and food and beverage production and a producer of biomass electricity generated in the process of producing activated carbon. The firm generates a majority of its revenue from Activated carbon.
About OGEN Oragenics Inc.
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.